Glenmark Pharma hits 52-week high on double-digit FY25 earnings growth target
Moneycontrol -

Glenmark Pharma soared as management's bullish FY25 targets offset weak quarterly earnings. Despite widening losses due to impairment charges, adjusted net profit nearly tripled, driven by a stake sale in Glenmark Life Sciences.

In related news